ClinicalTrials.gg

Program

Cyproterone Acetate

Also written as “Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)”, “Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg” and “Cyproterone acetate”.

Its studies are mostly in Acne Vulgaris · Adenocarcinoma · Hot Flashes, led by 3 companies.

Furthest: phase 3, since Mar 25, 20254 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eurofarma Laboratorios22 open or runningphase 3since Mar 25, 2025Mar 25, 2025Feb 2027phase 3 · NCT06905210
Takeda10 open or runningphase 3since Nov 3, 2009Nov 3, 2009none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since May 2, 2000May 2, 2000none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2000First study: phase 3 study in Hot FlashesNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00005623 · United States
  2. Nov 3, 2009Takeda's first study: phase 3 study in AdenocarcinomaNew to TakedaTakeda · NCT01011751 · 311 enrolled · France
  3. Mar 25, 2025Eurofarma Laboratorios's first study: phase 3 study in Acne VulgarisNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT06905210 · 531 planned · Brazil
  4. Jul 15, 2026Phase 3 study in ContraceptionEurofarma Laboratorios · NCT07714616 · 1,600 planned · Brazil

Ahead

  1. Feb 2027Primary completion: phase 3 study in Acne VulgarisEurofarma Laboratorios · NCT06905210
  2. May 31, 2029Primary completion: phase 3 study in ContraceptionEurofarma Laboratorios · NCT07714616

TargetBeta

“Androgen Receptor antagonist; Glucocorticoid receptor antagonist; Progesterone receptor agonist”ChEMBL 37, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07714616Contraception · Brazil3Not yet recruitingEurofarma LaboratoriosMay 31, 20291,600
NCT06905210Acne Vulgaris · Brazil3RecruitingEurofarma LaboratoriosFeb 2027531
NCT01011751Adenocarcinoma · France3CompletedTakedaDec 2007311
NCT00005623Hot Flashes · United States3CompletedTeva Pharmaceutical Industries

How it is read

Names in the registry

  • “Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)”, 1 entry
  • “Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg”, 1 entry
  • “Cyproterone acetate”, 1 entry
  • “cyproterone acetate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.